4 min read


United Kingdom-London: Software package and information systems

2020/S 207-506291

Contract award notice

Results of the procurement procedure

SuppliesLegal Basis:Directive 2014/24/EU

Section I: Contracting authorityI.1)Name and addressesOfficial name: MHRA Buyer Organisation
Town: London
Postal code: E14 4PU
Country: United Kingdom
E-mail: purchasing@mhra.gov.uk
Telephone: +44 2030806000
Internet address(es):
Main address: https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agencyI.4)Type of the contracting authorityMinistry or any other national or federal authority, including their regional or local subdivisionsI.5)Main activityHealth

Section II: ObjectII.1)Scope of the procurementII.1.1)Title:

SafetyConnect — AI

II.1.2)Main CPV code48000000 Software package and information systemsII.1.3)Type of contractSuppliesII.1.4)Short description:

The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs’ reaction text are missed.

II.1.6)Information about lotsThis contract is divided into lots: noII.1.7)Total value of the procurement (excluding VAT)Value excluding VAT: 1 500 000.00 GBPII.2)DescriptionII.2.2)Additional CPV code(s)48000000 Software package and information systemsII.2.3)Place of performanceNUTS code: UK UNITED KINGDOMII.2.4)Description of the procurement:

The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs’ reaction text are missed.

II.2.5)Award criteriaPriceII.2.11)Information about optionsOptions: noII.2.13)Information about European Union fundsThe procurement is related to a project and/or programme financed by European Union funds: noII.2.14)Additional information

Section IV: ProcedureIV.1)DescriptionIV.1.1)Type of procedureAward of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below

  • The procurement falls outside the scope of application of the directiveExplanation:

For reasons of extreme urgency under Regulation 32(2)(c) related to the release of a Covid-19 vaccine MHRA have accelerated the sourcing and implementation of a vaccine specific AI tool.

Strictly necessary — it is not possible to retrofit the MHRA’s legacy systems to handle the volume of ADRs that will be generated by a Covid-19 vaccine. Therefore, if the MHRA does not implement the AI tool, it will be unable to process these ADRs effectively. This will hinder its ability to rapidly identify any potential safety issues with the Covid-19 vaccine and represents a direct threat to patient life and public health.

Reasons of extreme urgency — the MHRA recognises that its planned procurement process for the SafetyConnect programme, including the AI tool, would not have concluded by vaccine launch. Leading to a inability to effectively monitor adverse reactions to a Covid-19 vaccine.

Events unforeseeable — the Covid-19 crisis is novel and developments in the search of a Covid-19 vaccine have not followed any predictable pattern so far.

IV.1.3)Information about a framework agreement or a dynamic purchasing systemIV.1.8)Information about the Government Procurement Agreement (GPA)The procurement is covered by the Government Procurement Agreement: yesIV.2)Administrative informationIV.2.8)Information about termination of dynamic purchasing systemIV.2.9)Information about termination of call for competition in the form of a prior information notice

Section V: Award of contractA contract/lot is awarded: yesV.2)Award of contractV.2.1)Date of conclusion of the contract:14/09/2020V.2.2)Information about tendersNumber of tenders received: 1The contract has been awarded to a group of economic operators: noV.2.3)Name and address of the contractorOfficial name: Genpact (UK) Ltd
Town: London
Country: United KingdomThe contractor is an SME: noV.2.4)Information on value of the contract/lot (excluding VAT)Total value of the contract/lot: 1 500 000.00 GBPV.2.5)Information about subcontracting

Section VI: Complementary informationVI.3)Additional information:VI.4)Procedures for reviewVI.4.1)Review bodyOfficial name: Medicines and Healthcare Products Agency
Town: London
Country: United KingdomVI.5)Date of dispatch of this notice:19/10/2020


Copy & Paste lenken øverst for Yandex oversettelse til Norsk.

WHO and WHAT is behind it all ? : >


The bottom line is for the people to regain their original, moral principles, which have intentionally been watered out over the past generations by our press, TV, and other media owned by the Illuminati/Bilderberger Group, corrupting our morals by making misbehaviour acceptable to our society. Only in this way shall we conquer this oncoming wave of evil.




All articles contained in Human-Synthesis are freely available and collected from the Internet. The interpretation of the contents is left to the readers and do not necessarily represent the views of the Administrator. Disclaimer: The contents of this article are of sole responsibility of the author(s). Human-Synthesis will not be responsible for any inaccurate or incorrect statement in this article. Human-Synthesis grants permission to cross-post original Human-Synthesis articles on community internet sites as long as the text & title are not modified.

The source and the author's copyright must be displayed. For publication of Human-Synthesis articles in print or other forms including commercial internet sites. Human-Synthesis contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.